Kusatsu, Japan

Yuki Yamamoto

This inventor holds 1 USPTO granted patent. Top assignee: Takara Bio Inc.. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuki Yamamoto. Retrieved from https://idiyas.com/inventor/yuki-yamamoto-8c38ol80

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yuki Yamamoto: Innovator in Endothelial Cell Production

Introduction

Yuki Yamamoto is a prominent inventor based in Kusatsu, Japan. She has made significant contributions to the field of regenerative medicine, particularly in the production of endothelial cells. Her innovative methods are paving the way for advancements in treatments for heart diseases.

Latest Patents

Yuki Yamamoto holds a patent for a method for producing endothelial cells. This method involves inducing a population of mesoderm-lineage cells containing endothelial progenitor cells from pluripotent stem cells without forming an embryoid body. The process includes culturing these cells in the presence of RepSox, which leads to the efficient production of high-quality endothelial cells. These cells are particularly useful for creating myocardial sheets, which can be utilized in heart disease treatments.

Career Highlights

Yuki Yamamoto is associated with Takara Bio Inc., where she continues to develop her groundbreaking research. Her work has garnered attention for its potential applications in regenerative medicine and cell therapy.

Collaborations

Yuki collaborates with esteemed colleagues such as Tatsuji Enoki and Yasuhiro Tosaka, contributing to a dynamic research environment that fosters innovation.

Conclusion

Yuki Yamamoto's contributions to the field of endothelial cell production exemplify the impact of innovative research in medicine. Her work not only advances scientific knowledge but also holds promise for improving patient outcomes in heart disease treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…